GGrantIndex
← Leaderboards

Michael T Lotze

University Of Pittsburgh At Pittsburgh

Google Scholar ↗PubMed ↗ORCID ↗
$5,139,928
Attributed
$5,777,145
Total exposure
13
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY2005–18
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$15,777,827 · 15

By mechanism

P01$13,503,189 · 8
R01$1,274,434 · 1
P30$500,808 · 1
P60$487,260 · 1
M01$12,136 · 4

Top collaborators

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject”

Research focus

Human SubjectClinical ResearchMelanomaNeoplasm /Cancer ImmunotherapyHuman Therapy EvaluationNeoplasm /Cancer ImmunologyClinical TrialsDendritic CellsNeoplasm /Cancer VaccineGene TherapyClinical Trial Phase ICytokineTissue /Cell CultureApoptosisHuman TissueSquamous Cell CarcinomaMetastasisMolecular OncologyMediatingAntineoplasticsFlow CytometryBaseInflammationImmunologic Assay /Test

Grant awards (56)

Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy$319,550
R01 · FY2018 · CA · contact PI
Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy$319,550
R01 · FY2016 · CA
Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy$319,550
R01 · FY2015 · CA
Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy$315,784
R01 · FY2014 · CA
Integrating NK and DC into Cancer Therapy$1,662,647
P01 · FY2009 · CA · contact PI
IL-1 HOMOLOGUES PROMOTE THE ACUTE INFLAMMATORY RESPONSE TO MELANOMA$523,876
P01 · FY2009 · CA · contact PI
Integrating NK and DC into Cancer Therapy$137,344
P01 · FY2009 · CA · contact PI
Integrating NK and DC into Cancer Therapy$1,625,933
P01 · FY2008 · CA · contact PI
IL-1 HOMOLOGUES PROMOTE THE ACUTE INFLAMMATORY RESPONSE TO MELANOMA$512,103
P01 · FY2008 · CA · contact PI
Integrating NK and DC into Cancer Therapy$1,458,286
P01 · FY2007 · CA · contact PI
IL-1 HOMOLOGUES PROMOTE THE ACUTE INFLAMMATORY RESPONSE TO MELANOMA$562,884
P01 · FY2007 · CA · contact PI
Integrating NK and DC into Cancer Therapy$107,376
P01 · FY2007 · CA · contact PI
Integrating NK and DC into Cancer Therapy$1,663,828
P01 · FY2006 · CA · contact PI
IL-1 HOMOLOGUES PROMOTE THE ACUTE INFLAMMATORY RESPONSE$285,303
P01 · FY2006 · CA · contact PI
Integrating NK and DC into Cancer Therapy$126,097
P01 · FY2006 · CA · contact PI
Integrating NK and DC into Cancer Therapy$1,677,415
P01 · FY2005 · CA
IL-1 HOMOLOGUES PROMOTE THE ACUTE INFLAMMATORY RESPONSE$281,729
P01 · FY2005 · CA
ADMINISTRATIVE CORE$239,767
P01 · FY2005 · CA
Biological therapeutics program$250,404
P30 · FY2002 · CA
APOPTOTIC PATHWAYS FOLLOWING CHEMOTHERAPY OR GENE THERAPY OF ORAL CANCER$162,420
P60 · FY2002 · DE
APOPTOTIC PATHWAYS FOLLOWING CHEMOTHERAPY OR GENE THERAPY OF ORAL CANCER$162,420
P60 · FY2002 · DE
PHASE I MELAN A/MART 1 GP100 TRIAL IN METASTATIC MELANOMA$0
M01 · FY2002 · RR
RANDOM EVALUATION OF IMMUNIZATION OF PATIENTS WITH METASTATIC MELANOMA$0
M01 · FY2002 · RR
RANDOM EVALUATION OF IMMUNIZATION OF PATIENTS WITH METASTATIC MELANOMA$0
M01 · FY2002 · RR
PHASE I MELAN A/MART 1 GP100 TRIAL IN METASTATIC MELANOMA$0
M01 · FY2002 · RR
IMMUNIZATION FOR METASTATIC MELANOMA WITH DENDRITIC CELLS$0
M01 · FY2002 · RR
IMMUNIZATION FOR METASTATIC MELANOMA WITH DENDRITIC CELLS$0
M01 · FY2002 · RR
PHASE 2 STUDY OF FLT3 LIGAND (FLT3) IN METASTATIC MELANOMA PATIENTS$0
M01 · FY2002 · RR
PHASE 2 STUDY OF FLT3 LIGAND (FLT3) IN METASTATIC MELANOMA PATIENTS$0
M01 · FY2002 · RR
DENDRITIC CELL THERAPIES ELICIT EFFECTIVE ANTITUMOR RESPONSES$0
P01 · FY2002 · CA
Biological therapeutics program$250,404
P30 · FY2001 · CA
GENE TRANSFECTION TO ENHANCE DENDRITIC AND ENDOTHELIAL CELL FUNCTION$168,360
P01 · FY2001 · CA
APOPTOTIC PATHWAYS FOLLOWING CHEMOTHERAPY OR GENE THERAPY OF ORAL CANCER$162,420
P60 · FY2001 · DE
ORAL CARCINOMA TREATMENT--INTERLEUKIN 12 AND GENE THERAPY$90,362
P01 · FY2001 · DE
Biological therapeutics program$0
P30 · FY2001 · CA
DENDRITIC CELL THERAPIES ELICIT EFFECTIVE ANTITUMOR RESPONSES$0
P01 · FY2001 · CA
IMMUNIZATION FOR METASTATIC MELANOMA WITH DENDRITIC CELLS$0
M01 · FY2001 · RR
PHASE I MELAN A/MART 1 GP100 TRIAL IN METASTATIC MELANOMA$0
M01 · FY2001 · RR
RANDOM EVALUATION OF IMMUNIZATION OF PATIENTS WITH METASTATIC MELANOMA$0
M01 · FY2001 · RR
DENDRITIC CELL THERAPY FOR HIV--ROLE OF CYTOKINES ON ENHANCED T CELL FUNCTION$0
P01 · FY2001 · AI
PHASE 2 STUDY OF FLT3 LIGAND (FLT3) IN METASTATIC MELANOMA PATIENTS$0
M01 · FY2001 · RR
DENDRITIC CELL BIOLOGY AND THERAPY$1,541,756
P01 · FY2000 · CA
DENDRITIC CELL THERAPY FOR HIV--ROLE OF CYTOKINES ON ENHANCED T CELL FUNCTION$213,937
P01 · FY2000 · AI
DENDRITIC CELL THERAPIES ELICIT EFFECTIVE ANTITUMOR RESPONSES$197,104
P01 · FY2000 · CA
GENE TRANSFECTION TO ENHANCE DENDRITIC AND ENDOTHELIAL CELL FUNCTION$168,360
P01 · FY2000 · CA
GENE TRANSFECTION TO ENHANCE DENDRITIC AND ENDOTHELIAL CELL FUNCTION$168,360
P01 · FY2000 · CA
ORAL CARCINOMA TREATMENT--INTERLEUKIN 12 AND GENE THERAPY$90,362
P01 · FY2000 · DE
PHASE I MELAN A/MART 1 GP100 TRIAL IN METASTATIC MELANOMA$3,034
M01 · FY2000 · RR
RANDOM EVALUATION OF IMMUNIZATION OF PATIENTS WITH METASTATIC MELANOMA$3,034
M01 · FY2000 · RR
PHASE 2 STUDY OF FLT3 LIGAND (FLT3) IN METASTATIC MELANOMA PATIENTS$3,034
M01 · FY2000 · RR
IMMUNIZATION FOR METASTATIC MELANOMA WITH DENDRITIC CELLS$3,034
M01 · FY2000 · RR
Biological therapeutics program$0
P30 · FY2000 · CA
APOPTOTIC PATHWAYS FOLLOWING CHEMOTHERAPY OR GENE THERAPY OF ORAL CANCER$0
P60 · FY2000 · DE
APOPTOTIC PATHWAYS FOLLOWING CHEMOTHERAPY OR GENE THERAPY OF ORAL CANCER$0
P60 · FY2000 · DE
APOPTOTIC PATHWAYS FOLLOWING CHEMOTHERAPY OR GENE THERAPY OF ORAL CANCER$0
P60 · FY2000 · DE
APOPTOTIC PATHWAYS FOLLOWING CHEMOTHERAPY OR GENE THERAPY OF ORAL CANCER$0
P60 · FY2000 · DE